Raymond James Upgrades Zymeworks, Says Encouraging Cancer Drug Is 'Born to Run'
Canadian biotech Zymeworks Inc. (NYSE: ZYME) over the weekend announced more data from an ongoing clinical trial of a drug to treat HER2-type cancers and announced a Phase 2 trial in another cancer drug, leading to a more bullish stance on the company’s stock from Raymond James.
The Analyst
Raymond James analyst David Novak upgraded Zymeworks from Outperform to Strong Buy while upping the target price from $36 to $40.
The Thesis
The new data presented at the ESMO conference demonstrates Zymeworks "was born to run," Novak wrote in a note.
The Vancouver-based biotech’s latest results, demonstrating what Novak called “highly encouraging antitumor activity,” could be a major step forward, he said, with the potential to “in time, transform the HER2 therapeutic landscape.
“With multiple potential clinical catalysts anticipated in the coming months, we expect additional positive data readouts, and thus are upgrading ZYME to a Strong Buy,” Novak wrote.
Price Action
Zymeworks shares traded around $24.79 at publication time.
Related Links:
The Week Ahead In Biotech: Conference Presentations, IPOs Hit Top Gear
The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study
Latest Ratings for ZYME
Sep 2019 | Upgrades | Outperform | Strong Buy | |
Aug 2019 | Initiates Coverage On | Buy | ||
Aug 2019 | Maintains | Buy |
View More Analyst Ratings for ZYME
View the Latest Analyst Ratings
See more from Benzinga
White House Revelations: Giuliani Subpoenaed By House Committee, Pompeo Listened To Zelensky Call
Sell-Side: Wells Fargo's New CEO A Good Hire, But Don't Look For A Quick Fix
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
